Artificial intelligence (AI) is quickly finding a place in all aspects of life in recent months – including fertility treatments.
In vitro fertilisation (IVF) company AIVF is using AI to “accelerate the time to pregnancy and increase predicted clinical pregnancy success rates” with what it describes as “some of the most sophisticated and well-tested fertility technologies available”.
The company says the technology was borne from five years of intensive research, with tens of thousands of embryos from five continents analysed using “state-of-the-art AI”.
Leveraging AI for fertility treatments
"We are excited to bring our innovative solutions to Australia, marking a significant step forward in our mission to support individuals and couples on their journey to parenthood," said Daniella Gilboa, CEO and co-founder of AIVF.
"Our technology is designed to provide a higher standard of care, improving clinical outcomes and optimising the IVF process."
AIVF has three separate AI-enabled models:
Embryo resilience model - an algorithm trained to identify embryo characteristics and biological scenarios that may occur during in vitro embryonic development as well as increase the effectiveness of medical interventions such as assisted hatching or artificial collapse.
Morphokinetics model - a deep learning-based algorithm trained to detect dynamic events during development.
Segmentation model - another deep learning-based algorithm that aids in detecting and measuring embryo shape, size, structure and positioning inside the culture dish well for meaningful and accurate image assessments by the machine learning model.
The company says its technology is designed to improve success rates and optimise outcomes for fertility treatment patients, from early-stage embryo evaluation to genetic testing.
The fertility treatment market in Australia was valued at US$527.82 million in 2023 and is expected to expand at a compounding annual growth rate (CAGR) of 3.5% from 2023 to 2030 to reach US$670.26 million in 2030.